Trial Profile
Phase I/IIa First-In-Human Study of EOS884448 in Participants With Advanced Cancers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Belrestotug (Primary)
- Indications Cancer; Haematological malignancies; Malignant melanoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors iTeos Therapeutics
- 15 Jun 2022 Status changed from active, no longer recruiting to completed.
- 29 Mar 2022 Planned End Date changed from 1 Apr 2022 to 1 Aug 2022.
- 29 Mar 2022 Planned primary completion date changed from 1 Oct 2021 to 27 Jul 2022.